Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee

NCT03005873 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT03005873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee
Lead sponsor
Taiwan Liposome Company
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2017
Completion date
July 4, 2018
Enrollment
76 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee